MINAKEM is a fully integrated development partner and commercial manufacturer for pharmaceutical companies. - API manufacturing (Innovators/Generics and Highly Potent) - Custom development (process development and optimization) - Custom manufacturing - Production of Key intermediates and building blocks All development and manufacturing activities are supported by highly skilled R&D technical centres, strong and state of the art analytical services including solid form and QBD laboratories. MINAKEM’s talented team also ensures high-quality services in Quality Assurance, Regulatory Affairs, Safety, Health and Environment (SHE). Minakem is a technology-driven company with expertise in complex multi-step synthesis, pressure chemistry, chiral synthesis, halogenation chemistry, steroid chemistry and “prazole” chemistry… Minakem has operations in 3 different sites, which are all US FDA and local health agencies approved and is : - Dunkirk, France – former AstraZeneca “prazoles” and budesonide production site - Beuvry-la-Forêt, France - Louvain-la-Neuve, Belgium – former Ajimonoto-Omnichem site, specialized in vinca alkaloids synthesis - Montréal , Canada - former Delmar site Strong synergies within MINAKEM facilities sites offer customers the flexibility, responsiveness and cost-effectiveness paired with the strong technical know-how to create significant added value within our customers’ supply chains. Minakem is part of the Minafin Group (link to Minafin site), and as such has access to all technologies, resources, and capabilities to respond to its client’s needs, especially with Leuna, Germany, and Pennakem (USA).
Looking for a particular MINAKEM employee's phone or email?
The MINAKEM annual revenue was $185.7 million in 2026.
Olivier Ubrich is the CEO of MINAKEM.
214 people are employed at MINAKEM.
MINAKEM is based in Beuvry la Forêt, Hauts de France.
The NAICS codes for MINAKEM are [32, 32541, 3254, 325].
The SIC codes for MINAKEM are [28, 283].